Seeking Alpha

Traders seem trigger happy on this news

Maybe traders are just desperate for any shred of good news but shares of pico cap RXI Pharmaceuticals (RXII +27.4%) pop in modestly higher volume after its report of positive results in a preclinical study on monkeys.

Investigators injected the company's anti-scarring drug RXI-109 into the eyes of cynomolgus monkeys to assess its effect on connective tissue growth factor (CTGF) proteins as part of a dose range-finding study.

Seven days after injection, whole eye sections were collected (ouch), tissue samples were affixed to slides and stained and then quantified by digital image analysis. Scientists observed reductions in CTGF proteins in a dose-dependent manner. The firm states that the results open up a possible development avenue for a topical form of RXI-109 to combat corneal scarring. This may be but there is a colossal amount of work yet to be done.

RXI-109 is an sd-rxRNA that targets the mRNA of CTGF, a gene known to modulate fibrosis and scar formation. Two Phase 2 trials are underway to assess its safety and effectiveness in scar revision surgeries.

Comments (2)
  • SimonSaysShort
    , contributor
    Comments (112) | Send Message
    Pico cap? That is just silly.
    2 May 2014, 10:25 AM Reply Like
  • bri52189
    , contributor
    Comments (7) | Send Message
    technology already validated in keloid/hypertrophic scars... this validates their optho pipeline (mac degen specifically) which has recently been funded 20Mil by lincoln park in chicago.


    In addition, watch for pre-clinical on liver fibrosis to be out soon... this company is a three headed monster and the CEO is very frugal with its money and has a great history in building huge companies.
    2 May 2014, 11:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs